Consider possibility of ovulation and conception before the first use of etonogestrel/ethinyl estradiol intravaginal ring. Levonorgestrel is used to prevent pregnancy after unprotected sexual intercourse (sex without any method of birth control or with a birth control method that failed or was not used properly [e.g., a condom that slipped or broke or birth control pills that were not taken as scheduled]).
/viewarticle/936111
Previous. If you log out, you will be required to enter your username and password the next time you visit. It is less androgenic than levonorgestrel and norethisterone, and it does not cause a decrease in sex hormone-binding globulin levels.
Mirena (levonorgestrel-releasing intrauterine device) and NuvaRing (etonogestrel and ethinyl estradiol vaginal ring) are forms of birth used to prevent pregnancy. Indicated for use by females of reproductive age to prevent pregnancyOne NuvaRing is inserted in the vagina and is to remain in place continuously for 3 weeksIt is removed for a one-week break, during which a withdrawal bleed usually occurs, THENA new ring is inserted 1 week after the last ring was removedSee Adminstration for details regarding when to insert ringIndicated for use by females of reproductive age to prevent pregnancyOne NuvaRing is inserted in the vagina and is to remain in place continuously for 3 weeksIt is removed for a 1-week break, during which a withdrawal bleed usually occurs, THENA new ring is inserted 1 week after the last ring was removedSee Adminstration for details regarding when to insert ringDevice-related events (eg, expulsion/discomfort/foreign body sensation) (6.3%)Immune system disorders: Hypersensitivity (anaphylaxis and angioedema)Nervous system disorders: Stroke/cerebrovascular accidentVascular disorders: Arterial events (including arterial thromboembolism and myocardial infarction), aggravation of varicose veinsSkin and subcutaneous tissue disorders: urticaria, chloasmaReproductive system and breast disorders: penile disorders, including local reactions on penis (in male partners of women using NuvaRing), galactorrheaInjury, poisoning and procedural complications: Vaginal injury (including associated pain, discomfort, and bleeding) associated with ring breakageArterial thromboembolic disease (stroke, MI), thrombophlebitis, DVT/PE, thrombogenic valvular diseaseEstrogen-dependent neoplasia (current or history of)Diabetes mellitus with vascular involvement, jaundice with prior oral contraceptive useAvoid using diaphragm concomitantly; may interfere with ring placementCurrent/history of depression, endometriosis, DM, HTN, bone mineral density changes, renal/hepatic impairment, bone metabolic disease, SLE; conditions exacerbated by fluid retention (eg, migraine, asthma, epilepsy)Discontinue if the following develop jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significang blood pressure increase, severe depression, increased risk of thromboembolic complications after surgeryDiscontinue 4 week before major surgery or prolonged immobilizationDiscontinue if an arterial thrombotic or venous thromboembolic event occursEstrogens may cause retinal vascular thrombosis; discontinue therapy if visual disturbances occur including migraine, loss of vision, diplopia, or proptosisPatients on warfarin, oral anticoagulants (increase in anticoagulant dose may be warranted)Some studies link OCP use with increased risk of breast cancer, whereas other studies have not shown a change in risk; woman's risk depends on conditions where naturally high hormone levels persist for long periods of time including early onset menstruation before age 12, late onset menopause, after age 55, first child after age 30, nulliparityIncreased risk of cervical cancer with OCP use, however HPV remains as main risk factor for this cancer, evidence suggests long-term use of OCPs, 5 or more years, may be associated with increased riskIncreased risk of liver cancer with OCP use; risk increases with longer duration of OCP useCombination of hormonal contraceptives may affect lipoprotein levels and serum triglyceridesIncreased risk of gallbladder disease reported (dose dependent)Use caution in patients with diseases that may be exacerbated by fluid retention including migraine, diabetes, renal dysfunction, and epilepsyCDC guidelines recommend waiting at least 3 weeks following vaginal birth or 6 weeks after cesarean section to decrease risk for venous thromboembolism before initiating combined hormonal contraceptives; women with additional risk factors for VTE (besides postpartum) should not use combined hormonal contraceptives (MMWR July 7, 2011)Ring may not be suitable for women with conditions that make vagina more susceptible to vaginal irritation or ulceration; vaginal/cervical erosion or ulceration in women reported; in some cases, the ring adhered to vaginal tissue, necessitating removal by a healthcare provider and in some instances (i.e., when tissue had grown over ring), removal was achieved by cutting the ring without incising the overlying vaginal tissueLactation: Small amounts of steroids are excreted in breast milk; estrogens may reduce quality/quantity of milk; may be prudent to use other forms of birth control until full weaning (AAP Committee states compatible w/ nursing)A: Generally acceptable.
Etonogestrel is a synthetic form of the naturally occurring female sex hormone progesterone.Etonogestrel binds to the cytoplasmic progesterone receptors in the reproductive system and subsequently activates progesterone receptor mediated gene expression.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. It can alter the menstrual cycle for 1-2 cycles. ; Levonorgestrel is a progestin.
Intravaginal Administration.
The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women[J].
The combination of Levonorgestrel and Ethinyl Estradiol is used in many different brands of hormonal birth control.
Etonogestrel is contraindicated for use during pregnancy or suspected pregnancy.
informational and educational purposes only.